Resource Summary Report

Generated by NIF on Jul 30, 2026

Brilliant Violet 650(TM) anti-mouse CD19

RRID:AB_11204087
Type: Antibody

Proper Citation

BioLegend Cat# 115541, RRID:AB_11204087

Antibody Information

URL: http://antibodyregistry.org/AB_11204087

Proper Citation: BioLegend Cat# 115541, RRID:AB_11204087

Target Antigen: CD19

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 650(TM) anti-mouse CD19

Description: This monoclonal targets CD19

Target Organism: mouse

Clone ID: Clone 6D5

Antibody ID: AB_11204087

Vendor: BioLegend

Catalog Number: 115541

Record Creation Time: 20250820T022311+0000

Record Last Update: 20250820T132712+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 650(TM) anti-mouse CD19.

No alerts have been found for Brilliant Violet 650(TM) anti-mouse CD19.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 42 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Farré Díaz C, et al. (2026) FOXO1 re-expression with a dual-recombinase allele rescues class switching in germinal center B cells. The Journal of experimental medicine, 223(3).

Xu Y, et al. (2026) A dysregulated hepcidin-iron axis impairs antiviral immunity and induces lethal liver pathology in neonates. Immunity, 59(1), 79.

Song H, et al. (2025) Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. Cancer cell, 43(3), 503.

Butler TD, et al. (2025) Colonic inflammation modulates the intestinal circadian landscape. iScience, 28(8), 113183.

Lanzar ZR, et al. (2025) IL-27 promotes Treg cell expression of CD122 and fitness at homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 122(50), e2519141122.

Mears KS, et al. (2025) Therapeutic activation of IL-22-producing innate lymphoid cells enhances host defenses to Clostridioides difficile infection. Cell reports, 44(4), 115438.

Ahn JJ, et al. (2025) Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity. Cell reports. Medicine, 6(8), 102257.

Lanzar ZR, et al. (2025) De-coupling immune parameters and toxicity associated with IL-12 agonism. Cell reports, 44(6), 115840.

Chen J, et al. (2025) Identification and validation of intratumoral microbiome associated with sensitization to immune checkpoint inhibitors. Cell reports. Medicine, 6(9), 102306.

Chandra V, et al. (2024) Gut epithelial Interleukin-17 receptor A signaling can modulate distant tumors growth through microbial regulation. Cancer cell, 42(1), 85.

Collins A, et al. (2024) Maternal inflammation regulates fetal emergency myelopoiesis. Cell, 187(6), 1402.

Denny JE, et al. (2024) Monoclonal antibody-mediated neutralization of Clostridioides difficile toxin does not diminish induction of the protective innate immune response to infection. Anaerobe, 88, 102859.

Xu L, et al. (2024) Expression of a mutant CD47 protects against phagocytosis without inducing cell death or inhibiting angiogenesis. Cell reports. Medicine, 5(3), 101450.

Wang B, et al. (2024) Intermittent clearance of p21-highly-expressing cells extends lifespan and confers sustained benefits to health and physical function. Cell metabolism, 36(8), 1795.

Zhang J, et al. (2024) Endothelial metabolic control of insulin sensitivity through resident macrophages. Cell metabolism, 36(11), 2383.

Kazer SW, et al. (2024) Primary nasal influenza infection rewires tissue-scale memory response dynamics. Immunity, 57(8), 1955.

Mahadevan KK, et al. (2023) Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T cells. Developmental cell, 58(17), 1562.

Chaudagar K, et al. (2023) Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(23), 4930.

Prokhnevska N, et al. (2023) CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity, 56(1), 107.

Eschweiler S, et al. (2023) JAML immunotherapy targets recently activated tumor-infiltrating CD8+ T cells. Cell reports, 42(2), 112040.